University of Minnesota. Driven to Discover.
In another new development, the NIH today announced the start of the first human trial of a live attenuated vaccine against Zika.
Trials of both an inactivated and a DNA vaccine showed good safety and immune response data.
The vaccine it has been developing with Walter Reed Army Institute of Research has been halted.
The patients, hospitalized at a speciality center, had a variety of complications and some unusual features.
In other Zika developments, a human rights group raised concerns about water, sanitation, and other public health concerns in Brazil, and India announced microcephaly screening for newborns.
A separate study found Zika virus in the saliva of 5 different mosquito species in Mexico.
The Florida study suggests a 'perfect storm' of conditions made Miami a favorable setting for Zika and that mosquito control helped reduce disease levels.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.